(Q36184471)

12 August 2017

1 reference

title

Psychotic symptoms in Parkinson's disease. From description to etiology (English)

1 reference

12 August 2017

1 reference

1 reference

Spiridon Papapetropoulos

series ordinal

1

1 reference

PubMed ID

15999234

12 August 2017

D C Mash

series ordinal

2

1 reference

12 August 2017

1 July 2005

1 reference

12 August 2017

1 reference

12 August 2017

252

1 reference

12 August 2017

7

1 reference

12 August 2017

753-764

1 reference

https://scigraph.springernature.com/pub.10.1007/s00415-005-0918-5

12 August 2017

0 references

cites work

Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0918-5

Psychosis and Other Psychiatric Manifestations of Levodopa Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0918-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0918-5

Prospective longitudinal assessment of hallucinations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0918-5

Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0918-5

Mortality and hallucinations in nursing home patients with advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0918-5

Risk factors for nursing home placement in advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0918-5

Early dopaminergic drug-induced hallucinations in parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0918-5

An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0918-5

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0918-5

Levodopa-induced psychosis: a kindling phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0918-5

Psychotic symptoms in Parkinson's disease patients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0918-5

Topography, Extent, and Clinical Relevance of Neurochemical Deficits in Dementia of Lewy Body Type, Parkinson's Disease, and Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0918-5

Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0918-5

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0918-5

Visual hallucinations associated with Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0918-5

Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0918-5

Psychiatric symptoms and syndromes in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0918-5

Mental symptoms in Parkinson's disease during chronic treatment with levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0918-5

Visual loss in Alzheimer's disease: out of sight, out of mind.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0918-5

Parkinsonism: onset, progression, and mortality

21 January 2018

1 reference

12 December 2020

Psychosis in Dementia With Lewy Bodies

1 reference

12 December 2020

Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).

1 reference

12 December 2020

Donepezil in the treatment of hallucinations and delusions in Parkinson's disease

1 reference

12 December 2020

Pharmacology of hallucinations induced by long-term drug therapy

1 reference

12 December 2020

Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease

1 reference

12 December 2020

Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.

1 reference

12 December 2020

Parkinson's disease and dementia with Lewy bodies: one disease or two?

1 reference

12 December 2020

Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series

1 reference

12 December 2020

Depression, psychosis and dementia in Parkinson's disease

1 reference

12 December 2020

1 reference

12 December 2020

Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease

1 reference

12 December 2020

Confusion, dementia and anticholinergics in Parkinson's disease

1 reference

12 December 2020

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

1 reference

12 December 2020

Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study

1 reference

12 December 2020

The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.

1 reference

12 December 2020

Tactile hallucinations in Parkinson's disease.

1 reference

12 December 2020

Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP.

1 reference

12 December 2020

Cenesthetic hallucinations in a patient with Parkinson's disease

1 reference

12 December 2020

Basal forebrain neurons in the dementia of Parkinson disease

1 reference

12 December 2020

Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson's disease

1 reference

12 December 2020

Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism

1 reference

12 December 2020

Fluctuations in attention: PD dementia vs DLB with parkinsonism

1 reference

12 December 2020

Unilateral MPTP-induced parkinsonism in monkeys. A quantitative autoradiographic study of dopamine D1 and D2 receptors and re-uptake sites

1 reference

12 December 2020

Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.

1 reference

12 December 2020

Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis.

1 reference

12 December 2020

Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study

1 reference

12 December 2020

Electrical and behavioral changes following thalamotomy

1 reference

12 December 2020

Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease

1 reference

12 December 2020

Biochemical pathophysiology of Parkinson's disease.

1 reference

12 December 2020

A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group.

1 reference

12 December 2020

Neuropsychiatric complications of medical and surgical therapies for Parkinson's disease

1 reference

12 December 2020

Binding of [3H]SCH 23390 to D-1 receptors in the putamen of control and parkinsonian subjects.

1 reference

12 December 2020

Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.

1 reference

12 December 2020

Deficits in cholinergic enzymes and muscarinic receptors in the hippocampus and striatum of senescent rats: effect of chronic hydergine treatment.

1 reference

12 December 2020

Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations.

1 reference

12 December 2020

Auditory hallucinations in Parkinson's disease

1 reference

12 December 2020

Hallucinations in Parkinson's disease: the clinical syndrome.

1 reference

12 December 2020

Dementia with Lewy bodies

1 reference

12 December 2020

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

1 reference

12 December 2020

Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease

1 reference

12 December 2020

A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia.

1 reference

12 December 2020

1 reference

12 December 2020

Evidence of a Monoaminergic-Cholinergic Imbalance Related to Visual Hallucinations in Lewy Body Dementia

1 reference

12 December 2020

Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease

1 reference

12 December 2020

A New Depression Scale Designed to be Sensitive to Change

1 reference

12 December 2020

Dementia and cognitive impairment in Parkinson's disease.

1 reference

12 December 2020

Donepezil for the treatment of psychosis in dementia with Lewy bodies

1 reference

12 December 2020

Parkinson's disease and sleep

1 reference

12 December 2020

Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis).

1 reference

12 December 2020

Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group

1 reference

12 December 2020

1 reference

12 December 2020

Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease.

1 reference

12 December 2020

Dopamine D-1 receptors in the parkinsonian brain

1 reference

12 December 2020

Visual hallucinations and the cholinergic system in dementia

1 reference

12 December 2020

Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease.

1 reference

12 December 2020

Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride

1 reference

12 December 2020

Managing the neuropsychiatric symptoms of Parkinson's disease

1 reference

12 December 2020

1 reference

12 December 2020

Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys

1 reference

12 December 2020

Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment.

1 reference

12 December 2020

PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease.

1 reference

12 December 2020

Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists

1 reference

12 December 2020

Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.

1 reference

12 December 2020

Prospective study of hallucinations and delusions in Parkinson's disease

1 reference

12 December 2020

Ondansetron for hallucinosis in advanced Parkinson's disease

1 reference

12 December 2020

Visual hallucinations in Parkinson's disease: a review and phenomenological survey

1 reference

12 December 2020

Dopaminergic psychosis in advanced Parkinson's disease

1 reference

12 December 2020

The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease

1 reference

12 December 2020

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

12 December 2020

Transplantation of embryonic dopamine neurons for severe Parkinson's disease

1 reference

12 December 2020

Neuropsychological prediction of dementia in Parkinson's disease

1 reference

12 December 2020

Treatment of drug-induced psychosis in Parkinson's disease with clozapine.

1 reference

12 December 2020

The role of serotonergic-cholinergic interactions in the mediation of cognitive behaviour

1 reference

12 December 2020

Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial

1 reference

12 December 2020

Switch-over from tolcapone to entacapone in severe Parkinson's disease patients

1 reference

12 December 2020

Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease.

1 reference

12 December 2020

Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine.

1 reference

12 December 2020

Development and validation of a geriatric depression screening scale: a preliminary report

1 reference

12 December 2020

Hallucinosis in idiopathic Parkinson's disease

1 reference

12 December 2020

Amantadine therapy in parkinsonism

1 reference

12 December 2020

Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease

1 reference

12 December 2020

10.1007/S00415-005-0918-5

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15999234